Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Generic Drugs and Old People Could Make You Rich

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

After tormenting investors for the past several years, CVS Caremark (NYSE: CVS  ) has been on a roll lately. Despite terrible returns, and its controversial and thus far unsuccessful attempt to combine the pharmacy benefit management business of Caremark with its retail pharmacy business, its stock has risen by more than a third since its September 2010 low.

Lamenting that you missed such a move? You shouldn't. For one, this return merely more-or-less matches the performance of the S&P 500 index over the same time period. More importantly, it's not too late to capitalize on a couple of significant catalysts that will likely send CVS' stock soaring in the coming years.

Ride the generic wave
CVS and other companies that fall under pharmacy benefit management and/or retail pharmacy banners, including Walgreens (NYSE: WAG  ) , Express Scripts (Nasdaq: ESRX  ) , and MedcoHealth Solutions (NYSE: MHS  ) , will likely see significantly better profit margins and increased profitability in the coming years, amid a wave of generic drug introductions between now and the year 2015.

The patents on most of the top-selling drugs in 2010 are scheduled to expire over the next several years. In the short term, this includes the introduction of a generic version of Pfizer's (NYSE: PFE  ) Lipitor, the United States' No. 1-selling drug in dollar terms, in November 2011. The country's third best-selling drug, Plavix, produced jointly by Sanofi-Aventis (NYSE: SNY  ) and Bristol-Myers Squibb (NYSE: BMY  ) , follows in May 2012. In the longer term, the patent on last year's No. 2-selling drug, AstraZeneca's Nexium, is scheduled to expire in 2014.   

It doesn't take consumers long to switch to generic forms of drugs once they are introduced. A recent study published by market intelligence firm IMS Health found that an average of 80% of branded medications' prescription volume is replaced by generic equivalents within half a year after losing patent protection.

The introduction of a significant number of generic drugs will be a boon for a number of companies, because generics are significantly more profitable than branded medications for pharmacies, distributors, and pharmacy benefit managers.

Feel the demographic tailwinds at your back
Not only will the drugs that CVS retails in the coming years be more profitable, but the company will also sell more of them to an aging U.S. population. According to the Census Bureau, the number of U.S. residents age 65 and older is expected to more than double by the middle of the next century, to 80 million. Furthermore, the number of "elderly" people in the country is expected to rise from approximately one in eight in 1994 to one in five by the year 2030.

These older Americans buy more prescription drugs on average than younger individuals. A study by the U.S. Department of Health and Human Services found that the total number of annual prescription purchases (including refills) rises from 9.3 for 18-to-44-year-olds to a whopping 31.6 for 65-to-74-year-olds.

I fully expect CVS to use its expanding customer base and higher-margin products to generate outstanding shareholder returns over the next several years. While several other companies will also benefit from these trends, CVS is cheaper than all of them when looking at a number of metrics, including its P/E and price-to-book value ratios. Furthermore, CVS's earnings have been held back by the lackluster performance of its Caremark benefit management business. Any improvement there, or divestiture of the division, could set CVS' stock aloft.

For related Foolishness:

Fool contributor Jason Knapp encourages you to Just Say No to Drugs, yet owns shares of CVS Caremark. Pfizer is a Motley Fool Inside Value selection. MedcoHealth Solutions is a Motley Fool Stock Advisor recommendation. The Fool owns shares of MedcoHealth Solutions. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (16)

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1488582, ~/Articles/ArticleHandler.aspx, 10/21/2016 7:54:02 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
CVS $87.41 Up +0.11 +0.13%
CVS Health CAPS Rating: ****
BMY $50.02 Down -0.34 -0.68%
Bristol-Myers Squi… CAPS Rating: ****
ESRX $69.61 Down -1.43 -2.01%
Express Scripts CAPS Rating: *****
MHS.DL $70.30 Down +0.00 +0.00%
Medco Health Solut… CAPS Rating: *****
PFE $32.18 Down -0.36 -1.11%
Pfizer CAPS Rating: ****
SNY $37.75 Down -0.32 -0.84%
Sanofi CAPS Rating: *****
WBA $81.57 Up +0.55 +0.68%
Walgreens Boots Al… CAPS Rating: ****